JP2009530274A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009530274A5 JP2009530274A5 JP2009500385A JP2009500385A JP2009530274A5 JP 2009530274 A5 JP2009530274 A5 JP 2009530274A5 JP 2009500385 A JP2009500385 A JP 2009500385A JP 2009500385 A JP2009500385 A JP 2009500385A JP 2009530274 A5 JP2009530274 A5 JP 2009530274A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- benzimidazol
- benzoyl
- bipyrrolidine
- pyrrolidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 cycloheteroalkyl Chemical group 0.000 claims 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 22
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- ZZCKGXAYSCVENO-UHFFFAOYSA-N 1-[[4-[(4-fluorobenzimidazol-1-yl)methyl]phenyl]methyl]-n,n-dimethylpyrrolidin-3-amine Chemical compound C1C(N(C)C)CCN1CC(C=C1)=CC=C1CN1C2=CC=CC(F)=C2N=C1 ZZCKGXAYSCVENO-UHFFFAOYSA-N 0.000 claims 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 2
- XKLNOVWDVMWTOB-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-carbazole Chemical compound N1C2=CC=CC=C2C2=C1CCCC2 XKLNOVWDVMWTOB-UHFFFAOYSA-N 0.000 claims 2
- GOYZVDIXNJVGAM-NRFANRHFSA-N 5-fluoro-1-[[4-[[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methyl]phenyl]methyl]benzimidazole Chemical compound N1([C@H]2CCN(C2)CC2=CC=C(C=C2)CN2C3=CC=C(C=C3N=C2)F)CCCC1 GOYZVDIXNJVGAM-NRFANRHFSA-N 0.000 claims 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- 102000004384 Histamine H3 receptors Human genes 0.000 claims 2
- 108090000981 Histamine H3 receptors Proteins 0.000 claims 2
- JZSKJBGVSGURIV-FQEVSTJZSA-N [4-[(5-fluorobenzimidazol-1-yl)methyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)CN2C3=CC=C(C=C3N=C2)F)CCCC1 JZSKJBGVSGURIV-FQEVSTJZSA-N 0.000 claims 2
- HKSPIQPSCHDGLG-NRFANRHFSA-N [4-[(6-chloro-2-methylbenzimidazol-1-yl)methyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)CN2C3=CC(Cl)=CC=C3N=C2C)CCCC1 HKSPIQPSCHDGLG-NRFANRHFSA-N 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- NKJNVVMJEBRTDJ-NRFANRHFSA-N (4-benzylphenyl)-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C=2C=CC(CC=3C=CC=CC=3)=CC=2)CCCC1 NKJNVVMJEBRTDJ-NRFANRHFSA-N 0.000 claims 1
- XNEFBIXQNVFRLQ-WIIYFNMSSA-N 1-[1-[4-[(3s)-3-pyrrolidin-1-ylpyrrolidine-1-carbonyl]phenyl]ethyl]indole-5-carbonitrile Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)C(C)N2C3=CC=C(C=C3C=C2)C#N)CCCC1 XNEFBIXQNVFRLQ-WIIYFNMSSA-N 0.000 claims 1
- WNYFCVHBWNPGFS-UHFFFAOYSA-N 1-[[2-chloro-4-[(3-piperidin-1-ylpyrrolidin-1-yl)methyl]phenyl]methyl]benzimidazole Chemical compound C=1C=C(CN2C3=CC=CC=C3N=C2)C(Cl)=CC=1CN(C1)CCC1N1CCCCC1 WNYFCVHBWNPGFS-UHFFFAOYSA-N 0.000 claims 1
- OAATWPVYGXYKIX-UHFFFAOYSA-N 1-[[2-chloro-4-[(3-pyrrolidin-1-ylpyrrolidin-1-yl)methyl]phenyl]methyl]benzimidazole Chemical compound C=1C=C(CN2C3=CC=CC=C3N=C2)C(Cl)=CC=1CN(C1)CCC1N1CCCC1 OAATWPVYGXYKIX-UHFFFAOYSA-N 0.000 claims 1
- FSCHBUFEORTTSK-UHFFFAOYSA-N 1-[[4-(benzimidazol-1-ylmethyl)-3-chlorophenyl]methyl]-n,n-dimethylpyrrolidin-3-amine Chemical compound C1C(N(C)C)CCN1CC(C=C1Cl)=CC=C1CN1C2=CC=CC=C2N=C1 FSCHBUFEORTTSK-UHFFFAOYSA-N 0.000 claims 1
- XIKKJGSHMQMXPV-UHFFFAOYSA-N 1-[[4-(benzimidazol-1-ylmethyl)-3-chlorophenyl]methyl]-n-ethyl-n-methylpyrrolidin-3-amine Chemical compound C1C(N(C)CC)CCN1CC(C=C1Cl)=CC=C1CN1C2=CC=CC=C2N=C1 XIKKJGSHMQMXPV-UHFFFAOYSA-N 0.000 claims 1
- FKYWWSRNAPEWLB-UHFFFAOYSA-N 1-[[4-(indol-1-ylmethyl)phenyl]methyl]-n,n-dimethylpyrrolidin-3-amine Chemical compound C1C(N(C)C)CCN1CC(C=C1)=CC=C1CN1C2=CC=CC=C2C=C1 FKYWWSRNAPEWLB-UHFFFAOYSA-N 0.000 claims 1
- ULCMJQLTPQGROK-UHFFFAOYSA-N 1-[[4-[(5-fluorobenzimidazol-1-yl)methyl]phenyl]methyl]-n,n-dimethylpyrrolidin-3-amine Chemical compound C1C(N(C)C)CCN1CC(C=C1)=CC=C1CN1C2=CC=C(F)C=C2N=C1 ULCMJQLTPQGROK-UHFFFAOYSA-N 0.000 claims 1
- QWRDXHCEAZUHDY-UHFFFAOYSA-N 1-[[4-[(6-fluorobenzimidazol-1-yl)methyl]phenyl]methyl]-n,n-dimethylpyrrolidin-3-amine Chemical compound C1C(N(C)C)CCN1CC(C=C1)=CC=C1CN1C2=CC(F)=CC=C2N=C1 QWRDXHCEAZUHDY-UHFFFAOYSA-N 0.000 claims 1
- LUEPEBVFWPXDQQ-QFIPXVFZSA-N 1-ethyl-2-[[4-[[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methyl]phenyl]methyl]benzimidazole Chemical compound N1([C@H]2CCN(C2)CC2=CC=C(C=C2)CC=2N(C3=CC=CC=C3N=2)CC)CCCC1 LUEPEBVFWPXDQQ-QFIPXVFZSA-N 0.000 claims 1
- OSZHOKFIDJUEGU-UHFFFAOYSA-N 4-fluoro-1-[[4-[(3-piperidin-1-ylpyrrolidin-1-yl)methyl]phenyl]methyl]benzimidazole Chemical compound C1=NC=2C(F)=CC=CC=2N1CC(C=C1)=CC=C1CN(C1)CCC1N1CCCCC1 OSZHOKFIDJUEGU-UHFFFAOYSA-N 0.000 claims 1
- ITAJFFQEBAKMJR-ZZWBGTBQSA-N 5-fluoro-1-[[4-[[3-[(2r)-2-methylpyrrolidin-1-yl]pyrrolidin-1-yl]methyl]phenyl]methyl]benzimidazole Chemical compound C[C@@H]1CCCN1C1CN(CC=2C=CC(CN3C4=CC=C(F)C=C4N=C3)=CC=2)CC1 ITAJFFQEBAKMJR-ZZWBGTBQSA-N 0.000 claims 1
- GZGMNXQGFBEWFA-NRFANRHFSA-N 6-fluoro-1-[[4-[[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methyl]phenyl]methyl]benzimidazole Chemical compound N1([C@H]2CCN(C2)CC2=CC=C(C=C2)CN2C=NC3=CC=C(C=C32)F)CCCC1 GZGMNXQGFBEWFA-NRFANRHFSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- XPFYAAVBFKWWSE-UHFFFAOYSA-N CC1N(CCCC1)C1CN(CC1)C(=O)C1=CC=C(CN2C=NC3=C2C=CC=C3)C=C1 Chemical compound CC1N(CCCC1)C1CN(CC1)C(=O)C1=CC=C(CN2C=NC3=C2C=CC=C3)C=C1 XPFYAAVBFKWWSE-UHFFFAOYSA-N 0.000 claims 1
- 208000012239 Developmental disease Diseases 0.000 claims 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- BZWDTZMVRVTPQF-NRFANRHFSA-N [(3s)-3-(azepan-1-yl)pyrrolidin-1-yl]-[4-[(7-fluorobenzimidazol-1-yl)methyl]phenyl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)CN2C=NC=3C=CC=C(C2=3)F)CCCCCC1 BZWDTZMVRVTPQF-NRFANRHFSA-N 0.000 claims 1
- YFOVYMUNACKLJM-SFHVURJKSA-N [(3s)-3-(azetidin-1-yl)pyrrolidin-1-yl]-[4-[(7-fluorobenzimidazol-1-yl)methyl]phenyl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)CN2C=NC=3C=CC=C(C2=3)F)CCC1 YFOVYMUNACKLJM-SFHVURJKSA-N 0.000 claims 1
- ZKAJTXVFCUQAHA-FQEVSTJZSA-N [(3s)-3-(dimethylamino)pyrrolidin-1-yl]-[4-[(1-methylindol-3-yl)methyl]phenyl]methanone Chemical compound C1[C@@H](N(C)C)CCN1C(=O)C(C=C1)=CC=C1CC1=CN(C)C2=CC=CC=C12 ZKAJTXVFCUQAHA-FQEVSTJZSA-N 0.000 claims 1
- AGGGVCYHWZMNEH-SFHVURJKSA-N [(3s)-3-[ethyl(methyl)amino]pyrrolidin-1-yl]-[4-[(7-fluorobenzimidazol-1-yl)methyl]phenyl]methanone Chemical compound C1[C@@H](N(C)CC)CCN1C(=O)C(C=C1)=CC=C1CN1C2=C(F)C=CC=C2N=C1 AGGGVCYHWZMNEH-SFHVURJKSA-N 0.000 claims 1
- CUHVFDRJOCNUTK-ACJLOTCBSA-N [(3s)-3-aminopyrrolidin-1-yl]-[4-[(1r)-1-(5-chloro-2-methylbenzimidazol-1-yl)ethyl]phenyl]methanone Chemical compound C1=CC([C@@H](C)N2C3=CC=C(Cl)C=C3N=C2C)=CC=C1C(=O)N1CC[C@H](N)C1 CUHVFDRJOCNUTK-ACJLOTCBSA-N 0.000 claims 1
- STRDTYMZVGDYCN-ACJLOTCBSA-N [(3s)-3-aminopyrrolidin-1-yl]-[4-[(1r)-1-(6-chloro-2-methylbenzimidazol-1-yl)ethyl]phenyl]methanone Chemical compound C1=CC([C@@H](C)N2C3=CC(Cl)=CC=C3N=C2C)=CC=C1C(=O)N1CC[C@H](N)C1 STRDTYMZVGDYCN-ACJLOTCBSA-N 0.000 claims 1
- CUHVFDRJOCNUTK-UGSOOPFHSA-N [(3s)-3-aminopyrrolidin-1-yl]-[4-[(1s)-1-(5-chloro-2-methylbenzimidazol-1-yl)ethyl]phenyl]methanone Chemical compound C1=CC([C@H](C)N2C3=CC=C(Cl)C=C3N=C2C)=CC=C1C(=O)N1CC[C@H](N)C1 CUHVFDRJOCNUTK-UGSOOPFHSA-N 0.000 claims 1
- STRDTYMZVGDYCN-UGSOOPFHSA-N [(3s)-3-aminopyrrolidin-1-yl]-[4-[(1s)-1-(6-chloro-2-methylbenzimidazol-1-yl)ethyl]phenyl]methanone Chemical compound C1=CC([C@H](C)N2C3=CC(Cl)=CC=C3N=C2C)=CC=C1C(=O)N1CC[C@H](N)C1 STRDTYMZVGDYCN-UGSOOPFHSA-N 0.000 claims 1
- OYJUQBUJIKMYLC-INIZCTEOSA-N [(3s)-3-aminopyrrolidin-1-yl]-[4-[(5-chlorobenzimidazol-1-yl)methyl]phenyl]methanone Chemical compound C1[C@@H](N)CCN1C(=O)C(C=C1)=CC=C1CN1C2=CC=C(Cl)C=C2N=C1 OYJUQBUJIKMYLC-INIZCTEOSA-N 0.000 claims 1
- MXFTYPZMFCWDGD-IBGZPJMESA-N [(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]-[4-[[2-(trifluoromethyl)benzimidazol-1-yl]methyl]phenyl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)CN2C3=CC=CC=C3N=C2C(F)(F)F)CCCC1 MXFTYPZMFCWDGD-IBGZPJMESA-N 0.000 claims 1
- IJIVJXMGORRXAU-UHFFFAOYSA-N [3-(2-benzylpyrrolidin-1-yl)pyrrolidin-1-yl]-[4-[(5-methylbenzimidazol-1-yl)methyl]phenyl]methanone Chemical compound C1=NC2=CC(C)=CC=C2N1CC(C=C1)=CC=C1C(=O)N(C1)CCC1N1CCCC1CC1=CC=CC=C1 IJIVJXMGORRXAU-UHFFFAOYSA-N 0.000 claims 1
- LPTXIOWQQHYDOK-UHFFFAOYSA-N [3-(azepan-1-yl)pyrrolidin-1-yl]-[4-[(5-methylbenzimidazol-1-yl)methyl]phenyl]methanone Chemical compound C1=NC2=CC(C)=CC=C2N1CC(C=C1)=CC=C1C(=O)N(C1)CCC1N1CCCCCC1 LPTXIOWQQHYDOK-UHFFFAOYSA-N 0.000 claims 1
- JQMJISOLRBAIJJ-UHFFFAOYSA-N [3-(azetidin-1-yl)pyrrolidin-1-yl]-[4-[(5-methylbenzimidazol-1-yl)methyl]phenyl]methanone Chemical compound C1=NC2=CC(C)=CC=C2N1CC(C=C1)=CC=C1C(=O)N(C1)CCC1N1CCC1 JQMJISOLRBAIJJ-UHFFFAOYSA-N 0.000 claims 1
- YHKWENOEKQIQIK-UHFFFAOYSA-N [3-(dimethylamino)pyrrolidin-1-yl]-[4-(indol-1-ylmethyl)phenyl]methanone Chemical compound C1C(N(C)C)CCN1C(=O)C(C=C1)=CC=C1CN1C2=CC=CC=C2C=C1 YHKWENOEKQIQIK-UHFFFAOYSA-N 0.000 claims 1
- UYKJSYAQDGARFD-UHFFFAOYSA-N [3-(dimethylamino)pyrrolidin-1-yl]-[4-[(2-phenylbenzimidazol-1-yl)methyl]phenyl]methanone Chemical compound C1C(N(C)C)CCN1C(=O)C(C=C1)=CC=C1CN1C2=CC=CC=C2N=C1C1=CC=CC=C1 UYKJSYAQDGARFD-UHFFFAOYSA-N 0.000 claims 1
- KMGRYCOPEWXFGC-UHFFFAOYSA-N [3-(dimethylamino)pyrrolidin-1-yl]-[4-[(4-fluorobenzimidazol-1-yl)methyl]phenyl]methanone Chemical compound C1C(N(C)C)CCN1C(=O)C(C=C1)=CC=C1CN1C2=CC=CC(F)=C2N=C1 KMGRYCOPEWXFGC-UHFFFAOYSA-N 0.000 claims 1
- LKKTYXFSXVJHDQ-UHFFFAOYSA-N [3-(dimethylamino)pyrrolidin-1-yl]-[4-[(5-fluorobenzimidazol-1-yl)methyl]phenyl]methanone Chemical compound C1C(N(C)C)CCN1C(=O)C(C=C1)=CC=C1CN1C2=CC=C(F)C=C2N=C1 LKKTYXFSXVJHDQ-UHFFFAOYSA-N 0.000 claims 1
- VUKGGORJGGCJMA-UHFFFAOYSA-N [3-(dimethylamino)pyrrolidin-1-yl]-[4-[(5-methylbenzimidazol-1-yl)methyl]phenyl]methanone Chemical compound C1C(N(C)C)CCN1C(=O)C(C=C1)=CC=C1CN1C2=CC=C(C)C=C2N=C1 VUKGGORJGGCJMA-UHFFFAOYSA-N 0.000 claims 1
- VGKWMGNAFBTILL-UHFFFAOYSA-N [3-(dimethylamino)pyrrolidin-1-yl]-[4-[(6-fluorobenzimidazol-1-yl)methyl]phenyl]methanone Chemical compound C1C(N(C)C)CCN1C(=O)C(C=C1)=CC=C1CN1C2=CC(F)=CC=C2N=C1 VGKWMGNAFBTILL-UHFFFAOYSA-N 0.000 claims 1
- MTWVKIPKXDPFST-UHFFFAOYSA-N [3-(dimethylamino)pyrrolidin-1-yl]-[4-[(6-methylbenzimidazol-1-yl)methyl]phenyl]methanone Chemical compound C1C(N(C)C)CCN1C(=O)C(C=C1)=CC=C1CN1C2=CC(C)=CC=C2N=C1 MTWVKIPKXDPFST-UHFFFAOYSA-N 0.000 claims 1
- HCQNTGCTJYYFSN-UHFFFAOYSA-N [3-[ethyl(methyl)amino]pyrrolidin-1-yl]-[4-[(5-methylbenzimidazol-1-yl)methyl]phenyl]methanone Chemical compound C1C(N(C)CC)CCN1C(=O)C(C=C1)=CC=C1CN1C2=CC=C(C)C=C2N=C1 HCQNTGCTJYYFSN-UHFFFAOYSA-N 0.000 claims 1
- CHXYRVONIWLABP-UHFFFAOYSA-N [4-(1h-benzimidazol-2-ylmethyl)phenyl]-(3-piperidin-1-ylpyrrolidin-1-yl)methanone Chemical compound C=1C=C(CC=2NC3=CC=CC=C3N=2)C=CC=1C(=O)N(C1)CCC1N1CCCCC1 CHXYRVONIWLABP-UHFFFAOYSA-N 0.000 claims 1
- HCASEGGSGZPNRG-UHFFFAOYSA-N [4-(1h-benzimidazol-2-ylmethyl)phenyl]-(3-pyrrolidin-1-ylpyrrolidin-1-yl)methanone Chemical compound C=1C=C(CC=2NC3=CC=CC=C3N=2)C=CC=1C(=O)N(C1)CCC1N1CCCC1 HCASEGGSGZPNRG-UHFFFAOYSA-N 0.000 claims 1
- RHHNYZPUWAFSQK-NRFANRHFSA-N [4-(1h-indol-3-ylmethyl)phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C=2C=CC(CC=3C4=CC=CC=C4NC=3)=CC=2)CCCC1 RHHNYZPUWAFSQK-NRFANRHFSA-N 0.000 claims 1
- MKFUTLJBZBYCCA-UHFFFAOYSA-N [4-(benzimidazol-1-ylmethyl)-2-fluorophenyl]-(3-pyrrolidin-1-ylpyrrolidin-1-yl)methanone Chemical compound FC1=CC(CN2C3=CC=CC=C3N=C2)=CC=C1C(=O)N(C1)CCC1N1CCCC1 MKFUTLJBZBYCCA-UHFFFAOYSA-N 0.000 claims 1
- LABNTHHPJNEGQR-UHFFFAOYSA-N [4-(benzimidazol-1-ylmethyl)-2-methoxyphenyl]-[3-(dimethylamino)pyrrolidin-1-yl]methanone Chemical compound COC1=CC(CN2C3=CC=CC=C3N=C2)=CC=C1C(=O)N1CCC(N(C)C)C1 LABNTHHPJNEGQR-UHFFFAOYSA-N 0.000 claims 1
- FLFNHBOROKVAFC-UHFFFAOYSA-N [4-(benzimidazol-1-ylmethyl)phenyl]-(3-piperidin-1-ylpiperidin-1-yl)methanone Chemical compound C=1C=C(CN2C3=CC=CC=C3N=C2)C=CC=1C(=O)N(C1)CCCC1N1CCCCC1 FLFNHBOROKVAFC-UHFFFAOYSA-N 0.000 claims 1
- WSVDCIDSNHAANT-UHFFFAOYSA-N [4-(benzimidazol-1-ylmethyl)phenyl]-(3-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound C=1C=C(CN2C3=CC=CC=C3N=C2)C=CC=1C(=O)N(C1)CCCC1N1CCCC1 WSVDCIDSNHAANT-UHFFFAOYSA-N 0.000 claims 1
- WMGFFKHQNCLGHB-WIYYLYMNSA-N [4-(benzimidazol-1-ylmethyl)phenyl]-[(3r)-3-[(2r)-2-methylpyrrolidin-1-yl]pyrrolidin-1-yl]methanone Chemical compound C[C@@H]1CCCN1[C@H]1CN(C(=O)C=2C=CC(CN3C4=CC=CC=C4N=C3)=CC=2)CC1 WMGFFKHQNCLGHB-WIYYLYMNSA-N 0.000 claims 1
- WMGFFKHQNCLGHB-GHTZIAJQSA-N [4-(benzimidazol-1-ylmethyl)phenyl]-[(3r)-3-[(2s)-2-methylpyrrolidin-1-yl]pyrrolidin-1-yl]methanone Chemical compound C[C@H]1CCCN1[C@H]1CN(C(=O)C=2C=CC(CN3C4=CC=CC=C4N=C3)=CC=2)CC1 WMGFFKHQNCLGHB-GHTZIAJQSA-N 0.000 claims 1
- RBFNAMZWICIZDO-UHFFFAOYSA-N [4-(benzimidazol-1-ylmethyl)phenyl]-[3-(2-methylpyrrolidin-1-yl)piperidin-1-yl]methanone Chemical compound CC1CCCN1C1CN(C(=O)C=2C=CC(CN3C4=CC=CC=C4N=C3)=CC=2)CCC1 RBFNAMZWICIZDO-UHFFFAOYSA-N 0.000 claims 1
- YOPCFDOLUZCVKR-UHFFFAOYSA-N [4-(benzimidazol-1-ylmethyl)phenyl]-[3-(4-methylpiperidin-1-yl)pyrrolidin-1-yl]methanone Chemical compound C1CC(C)CCN1C1CN(C(=O)C=2C=CC(CN3C4=CC=CC=C4N=C3)=CC=2)CC1 YOPCFDOLUZCVKR-UHFFFAOYSA-N 0.000 claims 1
- CCUDNLWFJUWTMY-AIBWNMTMSA-N [4-(indazol-1-ylmethyl)phenyl]-[1-[(3s)-pyrrolidin-3-yl]pyrrolidin-2-yl]methanone Chemical compound C=1C=C(CN2C3=CC=CC=C3C=N2)C=CC=1C(=O)C1CCCN1[C@H]1CCNC1 CCUDNLWFJUWTMY-AIBWNMTMSA-N 0.000 claims 1
- DZNOGNRCWAFGJA-BBQAJUCSSA-N [4-(indol-1-ylmethyl)phenyl]-[1-[(3s)-pyrrolidin-3-yl]pyrrolidin-2-yl]methanone Chemical compound C=1C=C(CN2C3=CC=CC=C3C=C2)C=CC=1C(=O)C1CCCN1[C@H]1CCNC1 DZNOGNRCWAFGJA-BBQAJUCSSA-N 0.000 claims 1
- GOYVYKRMDXBFOQ-UHFFFAOYSA-N [4-[(1-ethylbenzimidazol-2-yl)methyl]phenyl]-(3-pyrrolidin-1-ylpyrrolidin-1-yl)methanone Chemical compound N=1C2=CC=CC=C2N(CC)C=1CC(C=C1)=CC=C1C(=O)N(C1)CCC1N1CCCC1 GOYVYKRMDXBFOQ-UHFFFAOYSA-N 0.000 claims 1
- GOYVYKRMDXBFOQ-NRFANRHFSA-N [4-[(1-ethylbenzimidazol-2-yl)methyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)CC=2N(C3=CC=CC=C3N=2)CC)CCCC1 GOYVYKRMDXBFOQ-NRFANRHFSA-N 0.000 claims 1
- WRTHLXYYBTXQEW-UHFFFAOYSA-N [4-[(1-methylbenzimidazol-2-yl)methyl]phenyl]-(3-piperidin-1-ylpyrrolidin-1-yl)methanone Chemical compound N=1C2=CC=CC=C2N(C)C=1CC(C=C1)=CC=C1C(=O)N(C1)CCC1N1CCCCC1 WRTHLXYYBTXQEW-UHFFFAOYSA-N 0.000 claims 1
- IPNQUAFGDWXTMV-UHFFFAOYSA-N [4-[(1-methylbenzimidazol-2-yl)methyl]phenyl]-(3-pyrrolidin-1-ylpyrrolidin-1-yl)methanone Chemical compound N=1C2=CC=CC=C2N(C)C=1CC(C=C1)=CC=C1C(=O)N(C1)CCC1N1CCCC1 IPNQUAFGDWXTMV-UHFFFAOYSA-N 0.000 claims 1
- TYPMSXWMJDHEPY-QFIPXVFZSA-N [4-[(1-methylindol-3-yl)methyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)CC2=CN(C3=CC=CC=C32)C)CCCC1 TYPMSXWMJDHEPY-QFIPXVFZSA-N 0.000 claims 1
- CJHOAMPISBRSIJ-VWLOTQADSA-N [4-[(1-phenylbenzimidazol-2-yl)methyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C=2C=CC(CC=3N(C4=CC=CC=C4N=3)C=3C=CC=CC=3)=CC=2)CCCC1 CJHOAMPISBRSIJ-VWLOTQADSA-N 0.000 claims 1
- PTVLMBPOIJHSMZ-QFIPXVFZSA-N [4-[(1-propan-2-ylbenzimidazol-2-yl)methyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)CC=2N(C3=CC=CC=C3N=2)C(C)C)CCCC1 PTVLMBPOIJHSMZ-QFIPXVFZSA-N 0.000 claims 1
- IMEIHJWXQIJUEO-QFIPXVFZSA-N [4-[(1-propylbenzimidazol-2-yl)methyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)CC=2N(C3=CC=CC=C3N=2)CCC)CCCC1 IMEIHJWXQIJUEO-QFIPXVFZSA-N 0.000 claims 1
- QISUIGKPHXAXFI-VGSWGCGISA-N [4-[(1r)-1-(5-chloro-2-methylbenzimidazol-1-yl)ethyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)[C@@H](C)N2C3=CC=C(Cl)C=C3N=C2C)CCCC1 QISUIGKPHXAXFI-VGSWGCGISA-N 0.000 claims 1
- WEFBGFKYFBJFPI-VGSWGCGISA-N [4-[(1r)-1-(6-chloro-2-methylbenzimidazol-1-yl)ethyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)[C@@H](C)N2C3=CC(Cl)=CC=C3N=C2C)CCCC1 WEFBGFKYFBJFPI-VGSWGCGISA-N 0.000 claims 1
- QZPNKFJJDYDSGB-NQIIRXRSSA-N [4-[(1r)-1-(benzimidazol-1-yl)ethyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)[C@@H](C)N2C3=CC=CC=C3N=C2)CCCC1 QZPNKFJJDYDSGB-NQIIRXRSSA-N 0.000 claims 1
- QISUIGKPHXAXFI-JTSKRJEESA-N [4-[(1s)-1-(5-chloro-2-methylbenzimidazol-1-yl)ethyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)[C@H](C)N2C3=CC=C(Cl)C=C3N=C2C)CCCC1 QISUIGKPHXAXFI-JTSKRJEESA-N 0.000 claims 1
- WEFBGFKYFBJFPI-JTSKRJEESA-N [4-[(1s)-1-(6-chloro-2-methylbenzimidazol-1-yl)ethyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)[C@H](C)N2C3=CC(Cl)=CC=C3N=C2C)CCCC1 WEFBGFKYFBJFPI-JTSKRJEESA-N 0.000 claims 1
- QZPNKFJJDYDSGB-RXVVDRJESA-N [4-[(1s)-1-(benzimidazol-1-yl)ethyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)[C@H](C)N2C3=CC=CC=C3N=C2)CCCC1 QZPNKFJJDYDSGB-RXVVDRJESA-N 0.000 claims 1
- ADZIWICILUZNFO-UHFFFAOYSA-N [4-[(2-phenylbenzimidazol-1-yl)methyl]phenyl]-(3-pyrrolidin-1-ylpyrrolidin-1-yl)methanone Chemical compound C=1C=C(CN2C3=CC=CC=C3N=C2C=2C=CC=CC=2)C=CC=1C(=O)N(C1)CCC1N1CCCC1 ADZIWICILUZNFO-UHFFFAOYSA-N 0.000 claims 1
- FWMXBCISCWVQLF-UHFFFAOYSA-N [4-[(5-chloro-2-methylbenzimidazol-1-yl)methyl]phenyl]-(3-pyrrolidin-1-ylpyrrolidin-1-yl)methanone Chemical compound CC1=NC2=CC(Cl)=CC=C2N1CC(C=C1)=CC=C1C(=O)N(C1)CCC1N1CCCC1 FWMXBCISCWVQLF-UHFFFAOYSA-N 0.000 claims 1
- FWMXBCISCWVQLF-NRFANRHFSA-N [4-[(5-chloro-2-methylbenzimidazol-1-yl)methyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)CN2C3=CC=C(Cl)C=C3N=C2C)CCCC1 FWMXBCISCWVQLF-NRFANRHFSA-N 0.000 claims 1
- NXJVFLMPXBWWFL-FQEVSTJZSA-N [4-[(5-chlorobenzimidazol-1-yl)methyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)CN2C3=CC=C(C=C3N=C2)Cl)CCCC1 NXJVFLMPXBWWFL-FQEVSTJZSA-N 0.000 claims 1
- JZSKJBGVSGURIV-UHFFFAOYSA-N [4-[(5-fluorobenzimidazol-1-yl)methyl]phenyl]-(3-pyrrolidin-1-ylpyrrolidin-1-yl)methanone Chemical compound C1=NC2=CC(F)=CC=C2N1CC(C=C1)=CC=C1C(=O)N(C1)CCC1N1CCCC1 JZSKJBGVSGURIV-UHFFFAOYSA-N 0.000 claims 1
- XYZKJWCNULDFKE-OQHSHRKDSA-N [4-[(5-fluorobenzimidazol-1-yl)methyl]phenyl]-[3-[(2r)-2-methylpyrrolidin-1-yl]pyrrolidin-1-yl]methanone Chemical compound C[C@@H]1CCCN1C1CN(C(=O)C=2C=CC(CN3C4=CC=C(F)C=C4N=C3)=CC=2)CC1 XYZKJWCNULDFKE-OQHSHRKDSA-N 0.000 claims 1
- XYZKJWCNULDFKE-PBVYKCSPSA-N [4-[(5-fluorobenzimidazol-1-yl)methyl]phenyl]-[3-[(2s)-2-methylpyrrolidin-1-yl]pyrrolidin-1-yl]methanone Chemical compound C[C@H]1CCCN1C1CN(C(=O)C=2C=CC(CN3C4=CC=C(F)C=C4N=C3)=CC=2)CC1 XYZKJWCNULDFKE-PBVYKCSPSA-N 0.000 claims 1
- WJFWMSVIECSHGH-UHFFFAOYSA-N [4-[(5-methylbenzimidazol-1-yl)methyl]phenyl]-(3-morpholin-4-ylpyrrolidin-1-yl)methanone Chemical compound C1=NC2=CC(C)=CC=C2N1CC(C=C1)=CC=C1C(=O)N(C1)CCC1N1CCOCC1 WJFWMSVIECSHGH-UHFFFAOYSA-N 0.000 claims 1
- QMGPOQDFYWLZBM-UHFFFAOYSA-N [4-[(5-methylbenzimidazol-1-yl)methyl]phenyl]-(3-piperidin-1-ylpyrrolidin-1-yl)methanone Chemical compound C1=NC2=CC(C)=CC=C2N1CC(C=C1)=CC=C1C(=O)N(C1)CCC1N1CCCCC1 QMGPOQDFYWLZBM-UHFFFAOYSA-N 0.000 claims 1
- AWEAEUZMHXHUEQ-UHFFFAOYSA-N [4-[(5-methylbenzimidazol-1-yl)methyl]phenyl]-(3-pyrrolidin-1-ylpyrrolidin-1-yl)methanone Chemical compound C1=NC2=CC(C)=CC=C2N1CC(C=C1)=CC=C1C(=O)N(C1)CCC1N1CCCC1 AWEAEUZMHXHUEQ-UHFFFAOYSA-N 0.000 claims 1
- CLQSULFVKCGROH-UHFFFAOYSA-N [4-[(5-methylbenzimidazol-1-yl)methyl]phenyl]-[3-(3-methylpiperidin-1-yl)pyrrolidin-1-yl]methanone Chemical compound C1C(C)CCCN1C1CN(C(=O)C=2C=CC(CN3C4=CC=C(C)C=C4N=C3)=CC=2)CC1 CLQSULFVKCGROH-UHFFFAOYSA-N 0.000 claims 1
- LXRIHKRSUHOUJI-UHFFFAOYSA-N [4-[(5-methylbenzimidazol-1-yl)methyl]phenyl]-[3-(4-methyl-1,4-diazepan-1-yl)pyrrolidin-1-yl]methanone Chemical compound C1CN(C)CCCN1C1CN(C(=O)C=2C=CC(CN3C4=CC=C(C)C=C4N=C3)=CC=2)CC1 LXRIHKRSUHOUJI-UHFFFAOYSA-N 0.000 claims 1
- QHAIYCPEDMXVCO-UHFFFAOYSA-N [4-[(5-methylbenzimidazol-1-yl)methyl]phenyl]-[3-(4-methylpiperazin-1-yl)pyrrolidin-1-yl]methanone Chemical compound C1CN(C)CCN1C1CN(C(=O)C=2C=CC(CN3C4=CC=C(C)C=C4N=C3)=CC=2)CC1 QHAIYCPEDMXVCO-UHFFFAOYSA-N 0.000 claims 1
- IENOVDDWBKZXOA-UHFFFAOYSA-N [4-[(5-methylbenzimidazol-1-yl)methyl]phenyl]-[3-(4-methylpiperidin-1-yl)pyrrolidin-1-yl]methanone Chemical compound C1CC(C)CCN1C1CN(C(=O)C=2C=CC(CN3C4=CC=C(C)C=C4N=C3)=CC=2)CC1 IENOVDDWBKZXOA-UHFFFAOYSA-N 0.000 claims 1
- UBCMXYPKMPFNDM-LCQOSCCDSA-N [4-[(5-methylbenzimidazol-1-yl)methyl]phenyl]-[3-[(2r)-2-methylpyrrolidin-1-yl]pyrrolidin-1-yl]methanone Chemical compound C[C@@H]1CCCN1C1CN(C(=O)C=2C=CC(CN3C4=CC=C(C)C=C4N=C3)=CC=2)CC1 UBCMXYPKMPFNDM-LCQOSCCDSA-N 0.000 claims 1
- HKSPIQPSCHDGLG-UHFFFAOYSA-N [4-[(6-chloro-2-methylbenzimidazol-1-yl)methyl]phenyl]-(3-pyrrolidin-1-ylpyrrolidin-1-yl)methanone Chemical compound CC1=NC2=CC=C(Cl)C=C2N1CC(C=C1)=CC=C1C(=O)N(C1)CCC1N1CCCC1 HKSPIQPSCHDGLG-UHFFFAOYSA-N 0.000 claims 1
- MRKNAIPOYJRQES-FQEVSTJZSA-N [4-[(6-chlorobenzimidazol-1-yl)methyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)CN2C=NC3=CC=C(C=C32)Cl)CCCC1 MRKNAIPOYJRQES-FQEVSTJZSA-N 0.000 claims 1
- YRKMSCLZQSZISG-FQEVSTJZSA-N [4-[(6-fluorobenzimidazol-1-yl)methyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)CN2C=NC3=CC=C(C=C32)F)CCCC1 YRKMSCLZQSZISG-FQEVSTJZSA-N 0.000 claims 1
- LSSPPNVVJPOZKK-UHFFFAOYSA-N [4-[(6-methylbenzimidazol-1-yl)methyl]phenyl]-(3-pyrrolidin-1-ylpyrrolidin-1-yl)methanone Chemical compound C12=CC(C)=CC=C2N=CN1CC(C=C1)=CC=C1C(=O)N(C1)CCC1N1CCCC1 LSSPPNVVJPOZKK-UHFFFAOYSA-N 0.000 claims 1
- QRZWUPXCLYWBIP-NRFANRHFSA-N [4-[(7-chloroindol-1-yl)methyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)CN2C=CC=3C=CC=C(C2=3)Cl)CCCC1 QRZWUPXCLYWBIP-NRFANRHFSA-N 0.000 claims 1
- PXEMKQYDGBSBCY-ZYZRXSCRSA-N [4-[(7-fluorobenzimidazol-1-yl)methyl]phenyl]-[(3s)-3-(3-methylpiperidin-1-yl)pyrrolidin-1-yl]methanone Chemical compound C1C(C)CCCN1[C@@H]1CN(C(=O)C=2C=CC(CN3C4=C(F)C=CC=C4N=C3)=CC=2)CC1 PXEMKQYDGBSBCY-ZYZRXSCRSA-N 0.000 claims 1
- NTPRGPLMLQUNES-FQEVSTJZSA-N [4-[(7-fluorobenzimidazol-1-yl)methyl]phenyl]-[(3s)-3-piperidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)CN2C=NC=3C=CC=C(C2=3)F)CCCCC1 NTPRGPLMLQUNES-FQEVSTJZSA-N 0.000 claims 1
- YJVZLGCTQTWUQT-IBGZPJMESA-N [4-[(7-fluorobenzimidazol-1-yl)methyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)CN2C=NC=3C=CC=C(C2=3)F)CCCC1 YJVZLGCTQTWUQT-IBGZPJMESA-N 0.000 claims 1
- OIMGIFBNAHGVIY-UHFFFAOYSA-N [4-[(7-methylbenzimidazol-1-yl)methyl]phenyl]-(3-piperidin-1-ylpyrrolidin-1-yl)methanone Chemical compound C1=2C(C)=CC=CC=2N=CN1CC(C=C1)=CC=C1C(=O)N(C1)CCC1N1CCCCC1 OIMGIFBNAHGVIY-UHFFFAOYSA-N 0.000 claims 1
- OCNYXFGZHTZUMH-UHFFFAOYSA-N [4-[(7-methylbenzimidazol-1-yl)methyl]phenyl]-(3-pyrrolidin-1-ylpyrrolidin-1-yl)methanone Chemical compound C1=2C(C)=CC=CC=2N=CN1CC(C=C1)=CC=C1C(=O)N(C1)CCC1N1CCCC1 OCNYXFGZHTZUMH-UHFFFAOYSA-N 0.000 claims 1
- QISUIGKPHXAXFI-UGNFMNBCSA-N [4-[1-(5-chloro-2-methylbenzimidazol-1-yl)ethyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)C(C)N2C3=CC=C(Cl)C=C3N=C2C)CCCC1 QISUIGKPHXAXFI-UGNFMNBCSA-N 0.000 claims 1
- QYNQKOYWHMIKPG-IMMUGOHXSA-N [4-[1-(5-chloroindol-1-yl)ethyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)C(C)N2C3=CC=C(Cl)C=C3C=C2)CCCC1 QYNQKOYWHMIKPG-IMMUGOHXSA-N 0.000 claims 1
- RAIYGILFQRCQEQ-YSYXNDDBSA-N [4-[1-(7-chloroindol-1-yl)ethyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)C(C)N2C3=C(Cl)C=CC=C3C=C2)CCCC1 RAIYGILFQRCQEQ-YSYXNDDBSA-N 0.000 claims 1
- RNXMDOAIPPIROU-NRFANRHFSA-N [4-[[1-(2-hydroxyethyl)benzimidazol-2-yl]methyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)CC=2N(C3=CC=CC=C3N=2)CCO)CCCC1 RNXMDOAIPPIROU-NRFANRHFSA-N 0.000 claims 1
- DHAILTUFJZILPA-QFIPXVFZSA-N [4-[[1-(2-methoxyethyl)benzimidazol-2-yl]methyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)CC=2N(C3=CC=CC=C3N=2)CCOC)CCCC1 DHAILTUFJZILPA-QFIPXVFZSA-N 0.000 claims 1
- BIOPHEQFGYMNMQ-QHCPKHFHSA-N [4-[[1-(2-methylpropyl)benzimidazol-2-yl]methyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C2=CC=C(C=C2)CC=2N(C3=CC=CC=C3N=2)CC(C)C)CCCC1 BIOPHEQFGYMNMQ-QHCPKHFHSA-N 0.000 claims 1
- RWOANRMGKHQEHN-MHZLTWQESA-N [4-[[1-(2-phenylethyl)benzimidazol-2-yl]methyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C=2C=CC(CC=3N(C4=CC=CC=C4N=3)CCC=3C=CC=CC=3)=CC=2)CCCC1 RWOANRMGKHQEHN-MHZLTWQESA-N 0.000 claims 1
- DFBSUOQHUDIXGN-DEOSSOPVSA-N [4-[[1-(benzenesulfonyl)benzimidazol-2-yl]methyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C=2C=CC(CC=3N(C4=CC=CC=C4N=3)S(=O)(=O)C=3C=CC=CC=3)=CC=2)CCCC1 DFBSUOQHUDIXGN-DEOSSOPVSA-N 0.000 claims 1
- KARYDAVSGSBUHN-QHCPKHFHSA-N [4-[[1-(cyclopropylmethyl)benzimidazol-2-yl]methyl]phenyl]-[(3s)-3-pyrrolidin-1-ylpyrrolidin-1-yl]methanone Chemical compound N1([C@H]2CCN(C2)C(=O)C=2C=CC(CC=3N(C4=CC=CC=C4N=3)CC3CC3)=CC=2)CCCC1 KARYDAVSGSBUHN-QHCPKHFHSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 150000001556 benzimidazoles Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- WPSPMUYUGDFWLC-UHFFFAOYSA-N n,n-dimethyl-1-[[4-[(2-phenylbenzimidazol-1-yl)methyl]phenyl]methyl]pyrrolidin-3-amine Chemical compound C1C(N(C)C)CCN1CC(C=C1)=CC=C1CN1C2=CC=CC=C2N=C1C1=CC=CC=C1 WPSPMUYUGDFWLC-UHFFFAOYSA-N 0.000 claims 1
- OMPPJJVKMXILOM-UHFFFAOYSA-N n,n-dimethyl-1-[[4-[(6-methylbenzimidazol-1-yl)methyl]phenyl]methyl]pyrrolidin-3-amine Chemical compound C1C(N(C)C)CCN1CC(C=C1)=CC=C1CN1C2=CC(C)=CC=C2N=C1 OMPPJJVKMXILOM-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78251306P | 2006-03-15 | 2006-03-15 | |
| US85907906P | 2006-11-15 | 2006-11-15 | |
| PCT/US2007/005776 WO2007108936A2 (en) | 2006-03-15 | 2007-03-08 | N-substituted-azacyclylamines as histamine-3 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009530274A JP2009530274A (ja) | 2009-08-27 |
| JP2009530274A5 true JP2009530274A5 (enExample) | 2010-04-22 |
Family
ID=38353957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009500385A Withdrawn JP2009530274A (ja) | 2006-03-15 | 2007-03-08 | ヒスタミン−３アンタゴニストとしてのｎ−置換−アザシクリルアミン化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7820825B2 (enExample) |
| EP (1) | EP1994022A2 (enExample) |
| JP (1) | JP2009530274A (enExample) |
| AR (1) | AR059905A1 (enExample) |
| AU (1) | AU2007227681A1 (enExample) |
| BR (1) | BRPI0709612A2 (enExample) |
| CA (1) | CA2645731A1 (enExample) |
| MX (1) | MX2008011791A (enExample) |
| PE (1) | PE20071023A1 (enExample) |
| TW (1) | TW200800958A (enExample) |
| WO (1) | WO2007108936A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007531753A (ja) * | 2004-03-31 | 2007-11-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 非イミダゾール系複素環式化合物 |
| WO2007108936A2 (en) | 2006-03-15 | 2007-09-27 | Wyeth | N-substituted-azacyclylamines as histamine-3 antagonists |
| CA2649913A1 (en) | 2006-05-19 | 2007-11-29 | Wyeth | N-benzoyl- and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists |
| MX339668B (es) | 2006-05-30 | 2016-06-02 | Janssen Pharmaceutica N V * | Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina. |
| CN101511807A (zh) * | 2006-06-29 | 2009-08-19 | 詹森药业有限公司 | 组胺h3受体的取代的苯甲酰胺调节剂 |
| PE20081152A1 (es) | 2006-10-06 | 2008-08-10 | Wyeth Corp | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 |
| TW200823204A (en) * | 2006-10-17 | 2008-06-01 | Arena Pharm Inc | Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto |
| AR066721A1 (es) * | 2007-05-24 | 2009-09-09 | Wyeth Corp | Derivados de benzo[d]imidazol-1-il, composicion farmaceutica, proceso de preparacion y uso. |
| CA2693138A1 (en) | 2007-07-16 | 2009-01-22 | Wyeth Llc | Aminoalkylazole derivatives as histamine-3 antagonists |
| WO2009067406A1 (en) * | 2007-11-20 | 2009-05-28 | Janssen Pharmaceutica N.V. | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
| CN105712977B (zh) * | 2007-11-20 | 2021-06-29 | 詹森药业有限公司 | 作为组胺h3受体调节剂的环烷基氧基吡啶化合物和杂环烷基氧基吡啶化合物 |
| NZ597219A (en) * | 2009-06-26 | 2013-05-31 | Sanofi Sa | Novel fumarate salts of a histamine h3 receptor antagonist |
| JPWO2012102254A1 (ja) | 2011-01-25 | 2014-06-30 | キッセイ薬品工業株式会社 | インドール誘導体、またはその薬理学的に許容される塩 |
| CN104619693B (zh) * | 2012-07-17 | 2019-08-13 | 葛兰素史克知识产权第二有限公司 | 作为选择性雄激素受体调节剂的吲哚腈类 |
| JP6549735B2 (ja) | 2015-06-09 | 2019-07-24 | アッヴィ・インコーポレイテッド | 核内受容体調節剤 |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1416872A (en) | 1972-03-10 | 1975-12-10 | Wyeth John & Brother Ltd | 4-aminoquinoline derivatives |
| US3933829A (en) | 1974-08-22 | 1976-01-20 | John Wyeth & Brother Limited | 4-Aminoquinoline derivatives |
| US4159331A (en) | 1978-05-05 | 1979-06-26 | The Upjohn Company | Antihypertensive 4-aminoquinolines |
| US4166853A (en) | 1978-05-05 | 1979-09-04 | The Upjohn Company | Antihypertensive 7-trifluoromethyl-4-aminoquinolones |
| JPH05507469A (ja) | 1990-04-13 | 1993-10-28 | スミスクライン・ビーチャム・コーポレイション | 置換ベンズイミダゾール |
| CN1052224C (zh) | 1993-04-07 | 2000-05-10 | 大塚制药株式会社 | 哌啶衍生物、含有它的外周血管舒张剂及其应用 |
| IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| US6034093A (en) * | 1995-06-07 | 2000-03-07 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds |
| ATE253359T1 (de) | 1997-05-01 | 2003-11-15 | Lilly Co Eli | Antithrombotische mittel |
| US7375125B2 (en) * | 1999-08-04 | 2008-05-20 | Ore Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| US6699873B1 (en) * | 1999-08-04 | 2004-03-02 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| AU1734401A (en) | 1999-12-09 | 2001-06-18 | Mitsubishi Pharma Corporation | Carboxyamido derivatives |
| ATE430730T1 (de) | 2000-03-31 | 2009-05-15 | Ortho Mcneil Pharm Inc | Phenyl-substituierte indole als h3 histaminrezeptorantagonisten |
| JP2004515496A (ja) | 2000-12-07 | 2004-05-27 | アストラゼネカ・アクチエボラーグ | ベンズイミダゾール治療剤 |
| HN2002000156A (es) | 2001-07-06 | 2003-11-27 | Inc Agouron Pharmaceuticals | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización. |
| MXPA04009541A (es) | 2002-03-29 | 2005-01-25 | Chiron Corp | Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf. |
| EP1603917B1 (en) | 2003-03-14 | 2010-11-24 | MediGene Ltd. | Immunomodulating heterocyclic compounds |
| CA2561628C (en) * | 2004-04-01 | 2012-05-08 | Eli Lilly And Company | Histamine h3 receptor agents, preparation and therapeutic uses |
| KR101792651B1 (ko) | 2004-05-14 | 2017-11-20 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물 |
| TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
| US20060014733A1 (en) * | 2004-07-19 | 2006-01-19 | Pfizer Inc | Histamine-3 agonists and antagonists |
| DK1786790T3 (da) | 2004-07-26 | 2009-07-20 | Lilly Co Eli | Oxazolderivater som histamin H3 receptorstoffer, fremstilling og terapeutiske anvendelser |
| EP1784400B1 (en) | 2004-08-23 | 2015-01-14 | Eli Lilly And Company | Histamine h3 receptor agents, preparation and therapeutic uses |
| EP1791835A2 (en) * | 2004-09-09 | 2007-06-06 | Astellas Pharma Inc. | Thiazole derivatives having vap-1 inhibitory activity |
| UY29149A1 (es) | 2004-10-07 | 2006-05-31 | Boehringer Ingelheim Int | Tiazolil-dihidro-indazoles |
| US7381732B2 (en) | 2004-10-26 | 2008-06-03 | Bristol-Myers Squibb Company | Pyrazolobenzamides and derivatives as factor Xa inhibitors |
| EP1848696A1 (en) | 2005-01-21 | 2007-10-31 | Schering Corporation | Imidazole and benzimidazole derivates useful as histamine h3 antagonists |
| US20070032475A1 (en) | 2005-04-15 | 2007-02-08 | Ye Xiaocong M | Novel compounds useful for bradykinin B1 receptor antagonism |
| WO2007108936A2 (en) | 2006-03-15 | 2007-09-27 | Wyeth | N-substituted-azacyclylamines as histamine-3 antagonists |
| TW200812975A (en) | 2006-03-20 | 2008-03-16 | Glaxo Group Ltd | Compounds which potentiate AMPA receptor and uses thereof in medicine |
| US20070238718A1 (en) | 2006-04-06 | 2007-10-11 | Matthias Grauert | Thiazolyl-dihydro-indazole |
| CA2649913A1 (en) * | 2006-05-19 | 2007-11-29 | Wyeth | N-benzoyl- and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists |
| PE20081152A1 (es) * | 2006-10-06 | 2008-08-10 | Wyeth Corp | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 |
-
2007
- 2007-03-08 WO PCT/US2007/005776 patent/WO2007108936A2/en not_active Ceased
- 2007-03-08 EP EP07752471A patent/EP1994022A2/en not_active Withdrawn
- 2007-03-08 AU AU2007227681A patent/AU2007227681A1/en not_active Abandoned
- 2007-03-08 CA CA002645731A patent/CA2645731A1/en not_active Abandoned
- 2007-03-08 BR BRPI0709612-7A patent/BRPI0709612A2/pt not_active Application Discontinuation
- 2007-03-08 JP JP2009500385A patent/JP2009530274A/ja not_active Withdrawn
- 2007-03-08 MX MX2008011791A patent/MX2008011791A/es unknown
- 2007-03-13 PE PE2007000268A patent/PE20071023A1/es not_active Application Discontinuation
- 2007-03-13 TW TW096108558A patent/TW200800958A/zh unknown
- 2007-03-14 US US11/724,078 patent/US7820825B2/en not_active Expired - Fee Related
- 2007-03-15 AR ARP070101063A patent/AR059905A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013516415A5 (enExample) | ||
| AU2013354226B2 (en) | Novel benzimidazole derivatives as EP4 antagonists | |
| JP5157892B2 (ja) | アミド誘導体またはその塩 | |
| AU2007267859B2 (en) | Triazole compounds that modulate Hsp90 activity | |
| RU2406725C2 (ru) | Соединения и композиции как ингибиторы протеинкиназы | |
| AU2005247746B2 (en) | Cinnamide compound | |
| JP3822494B2 (ja) | チロシンキナーゼ阻害剤 | |
| JP2012525332A5 (enExample) | ||
| US7148249B2 (en) | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | |
| JP2019077725A5 (enExample) | ||
| US8653063B2 (en) | N-substituted saturated heterocyclic sulfone compounds with CB2 receptor agonistic activity | |
| EA038972B1 (ru) | Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9 | |
| TW201002685A (en) | Heterocyclic compound and use thereof | |
| JP2014532619A5 (enExample) | ||
| CA2653217A1 (en) | Method for treating proliferative disorders associated with protooncogene products | |
| RU2008147543A (ru) | Агонисты мускариновых рецепторов, эффективные при лечении боли, болезни альцгеймера и шизофрении | |
| RU2013157374A (ru) | Производное индазола и пирролопиридина и его фармацевтическое применение | |
| JP2009530274A (ja) | ヒスタミン−３アンタゴニストとしてのｎ−置換−アザシクリルアミン化合物 | |
| RU2016112952A (ru) | Производные индола и индазола | |
| CN101072759A (zh) | 调节hsp90活性的三唑化合物 | |
| RU2008120850A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| RU2329254C2 (ru) | Производные бензимидазола, композиции, содержащие их, их получение и их применение | |
| JP2011506566A5 (enExample) | ||
| EA010031B1 (ru) | Производные имидазола, способы их получения и применения | |
| CN102015697B (zh) | 酰胺衍生物以及含有该酰胺衍生物的药物组合物 |